Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate

Saved in:
Bibliographic Details
Published inNihon rinshō Vol. 65 Suppl 9; p. 365
Main Author Kishimoto, Hideaki
Format Journal Article
LanguageJapanese
Published Japan 28.11.2007
Subjects
Alendronate - administration & dosage
Alendronate - adverse effects
Bone Density
Bone Density Conservation Agents - administration & dosage
Bone Density Conservation Agents - adverse effects
Bone Remodeling
Clinical Trials as Topic
Double-Blind Method
Etidronic Acid - administration & dosage
Etidronic Acid - adverse effects
Etidronic Acid - analogs & derivatives
Gastrointestinal Diseases - chemically induced
Humans
Lumbar Vertebrae - metabolism
Osteoporosis - complications
Osteoporosis - drug therapy
Osteoporosis - metabolism
Patient Compliance
Risedronate Sodium
Spinal Fractures - epidemiology
Spinal Fractures - etiology
Spinal Fractures - prevention & control
Online AccessGet more information

Cover

More Information
ISSN:0047-1852